FIGURE 5.

CXCL9 expression is significantly higher in the immune‐inflamed and immune‐active phenotypes based on the IMvigor210 cohort. (A) Heatmap representing the CIBERSORT analysis, which assesses the correlation between the expression level of CXCL9 and 22 different types of immune cells. (B and C) Expression levels of CXCL9 in the previously defined three immune phenotypes (B) and the four immune phenotypes (C). (D and E) Expression levels of CXCL9 across different PD‐L1 expression levels by immune cells (D) and tumor cells (E). (F) Difference in expression levels of immune checkpoints between the high and low CXCL9 expression groups. (G and H) Spearman correlation analysis investigating the correlation between CXCL9 and immune checkpoints. GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DEGs, differentially expressed genes; PD‐1, anti‐programmed cell death‐1; PD‐L1, programmed cell death‐ligand 1; CTLA4, cytotoxic T‐lymphocyte‐associated protein 4; IDO1, indoleamine 2,3‐dioxygenase, LAG3, lymphocyte‐activation gene 3; IC, immune cells; TC, tumor cells. In (B–E), the significance of the difference was tested by Kruskal–Wallis test. In (F), ***p‐value ≤ 0.001.